Bioanalytical and DMPK Core
Bioanalytical and DMPK Core
批准号:
8788724
负责人:
John Scott Daniels
金额:
$33.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AdherenceAdoptedBehavioralBehavioral ModelBiologicalBiological AssayCanis familiarisChemicalsClinicalClinical ResearchComplexComputer softwareDataData AnalysesDevelopmentDoseDrug IndustryDrug KineticsEnsureEquipmentFoundationsGRM5 geneGoalsHalf-LifeHumanHuman ResourcesIn VitroIndustryInjection of therapeutic agentInstructionInvestigationLeadLinkLiquid ChromatographyMajor Depressive DisorderMental DepressionMetabolicMetabolic BiotransformationMetabolismMethodologyModelingMolecularNeuropharmacologyNeurosciencesPharmaceutical ChemistryPharmacologic SubstancePharmacologyPhasePlasmaPrincipal InvestigatorPropertyRattusResearch ContractsResearch DesignResearch PersonnelRodentRodent ModelSafetySamplingScientistSeriesSerumShapesStagingTestingTimeTissuesToxic effectTranslationsUrinebasebehavioral pharmacologydata modelingdrug discoverydrug metabolismexperiencein vivoliquid chromatography mass spectrometrymethod developmentnonhuman primatepharmacokinetic characteristicpre-clinicalprogramsresearch and developmentscaffoldscreeningtandem mass spectrometrytool
中文摘要
项目概述(见说明书):生物分析和DMPK核心将在以下发现和临床前开发项目(1,2)中提供高通量体外筛选和LC/MS/MS生物分析支持:1)执行一级DMPK筛选;2)对mGlu5 NAM发现化合物进行啮齿动物PK评估和随后的生物分析,并评估犬类和非人灵长类动物外部测试化合物的PK特性;3)对mGIU5候选发现在抑郁症啮齿动物模型中的行为药理学评估产生的生物培养基进行生物分析,并建立研究的PK/PD关系。核心中心由具有制药行业经验的关键人员组成,特别是具有药物代谢和药代动力学(PK)研究和开发经验的人员,将协助PK研究设计,协调来自临床前药理学的生物培养基样本的接收和储存,确定PK研究和非关键毒性研究,以及来自1期临床研究的血浆和尿液样本。Core还将实施Tier 1 DMPK筛选,包括随后的体外生物分析。DMPK科学家将采用现代的LC/MS/MS生物分析方法,采用最先进的质谱和液相色谱设备,并遵守适用于非onglp PK研究的监管指南。最后,丹尼尔斯博士和他的DMPK团队将使用行业标准软件对数据进行PK分析,该软件能够对非临床研究产生的时间浓度曲线进行建模。
英文摘要
PROJECT SUMMARY (See instructions): The Bioanalytical and DMPK Core will provide high throughput in vitro screening and LC/MS/MS bioanalytical support in the following discovery and preclinical development Projects (1, 2) identified within this application: 1) perform the Tier 1 DMPK screening of; 2) perform the rodent PK assessment and subsequent bioanalysis of mGlu5 NAM discovery compounds as well as assess the PK properties of compounds testing externally in dogs and nonhuman primates; and 3) perform the bioanalysis of biological media originating from the behavioral pharmacology assessment of mGIU5 discovery candidates in rodent models of depression, as well as establish PK/PD relationships of said studies. Built with key personnel possessing experience from the pharmaceutical industry, specifically from drug metabolism and pharmacokinetic (PK) research and development experience, the Core will aid in PK study design, coordinate the receipt and storage of biological media samples originating from preclinical pharmacology, definitive PK studies and nonpivotal toxicity studies, as well as plasma and urine samples originating from Phase 1 clinical studies. The Core will also implement the Tier 1 DMPK screen, including subsequent in vitro bioanalysis. The DMPK scientist will adopt a contemporary approach to LC/MS/MS based bioanalysis employing state-of-the-art mass spectrometry and liquid chromatography equipment and an adherence to regulatory guidances appropriate for the nonGLP PK studies. Finally, Dr. Daniels and his DMPK team will perform PK analysis of the data employing industry-standard software capable of modeling time concentration profiles generated from nonclinical studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Allosteric modulators of the glucagon-like peptide-1 receptor
-
批准号:8629044
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2014
-
负责人:John Scott Daniels
-
依托单位:
DMPK
-
批准号:8337497
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2008
-
负责人:John Scott Daniels
-
依托单位:
Bioanalytical and DMPK Core
-
批准号:8603877
-
项目类别:
-
资助金额:$33.56万
-
财政年份:--
-
负责人:John Scott Daniels
-
依托单位:
Bioanalytical and DMPK Core
-
批准号:8585977
-
项目类别:
-
资助金额:$37.29万
-
财政年份:--
-
负责人:John Scott Daniels
-
依托单位:
海外基金